The main idea is connected with a balance in the activity between oncogenes and tumor-suppressor genes, but also between the protein products of both gene types, on cellular and organism levels, both in vitro and in vivo. In this aspect, the main goal is directed to design of maximally safe experimental models for providing, on the one hand, of active tumor-suppressor genes for prevention of eventual malignant transformations, and, on the other hand, of active oncogenes for prevention of early aging and death. Also, adequate cell and/or humoral immune response against side effects, both in vitro and in vivo, should be generated, mainly by the protein products of the oncogenes in their role of active antigens. For gene transfer in laboratory-cultivated normal and malignant cells, as well as in single-cell yeast and bacteria strains, previously designed recombinant gene/DNA constructs, containing the respective genes of interest, but also, on the other hand, appropriate siRNAs for RNA-interference to specific regions of the respective target genes, are necessary. Subsequent investigations on the respective proteins, as well as protein-protein, protein-DNA, protein-RNA, RNA-RNA, RNA-DNA, DNA-DNA, etc. inter-molecular interactions, on both extra-and intra-cellular levels, should also be performed.

Molecular biotechnology, molecular and cellular biology.